Antigen processing by nardilysin and thimet oligopeptidase generates cytotoxic T cell epitopes

Nature Immunology

Volumn 12, Issue 1, 2011, Pages 45-53

  Kessler, Jan H ^a   Khan, Selina ^a   Seifert, Ulrike ^b   Le Gall, Sylvie ^c   Chow, K Martin ^d   Paschen, Annette ^e   Bres Vloemans, Sandra A ^a   De Ru, Arnoud ^a   Van Montfoort, Nadine ^a   Franken, Kees L M C ^a   Benckhuijsen, Willemien E ^a   Brooks, Jill M ^f   Van Hall, Thorbald ^a   Ray, Kallol ^d   Mulder, Arend ^a   Doxiadis, Ilias I N ^a   Van Swieten, Paul F ^g   Overkleeft, Hermen S ^g   Prat, Annik ^h   Tomkinson, Birgitta ⁱ   Neefjes, Jacques ^j   Kloetzel, Peter M ^b   Rodgers, David W ^d   Hersh, Louis B ^d   Drijfhout, Jan W ^a   Van Veelen, Peter A ^a   Ossendorp, Ferry ^a   Melief, Cornelis J M ^a   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HUMBOLDT UNIVERSITY   (Germany)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g LEIDEN UNIVERSITY   (Netherlands)

^h CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

ⁱ UPPSALA UNIVERSITY   (Sweden)

^j NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 1; MELAN A; NARDILYSIN; PRAME; PROTEASOME; PROTEINASE; THIMET OLIGOPEPTIDASE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ALLELE; ANTIGEN PRESENTATION; ANTIGENICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNITY; NEOPLASM; PRIORITY JOURNAL;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HLA-A3 ANTIGEN; HUMANS; K562 CELLS; METALLOENDOPEPTIDASES; PEPTIDE FRAGMENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; RNA, SMALL INTERFERING; T-LYMPHOCYTES, CYTOTOXIC; TRANSGENES;

EID: 78650310807     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.1974     Document Type: Article

References (50)

1. Rock, K.L., York, I.A. & Goldberg, A.L. Post-proteasomal antigen processing for major histocompatibility complex class I presentation. Nat. Immunol. 5, 670-677 (2004).
2. Shastri, N., Cardinaud, S., Schwab, S.R., Serwold, T. & Kunisawa, J. All the peptides that ft: the beginning, the middle, and the end of the MHC class I antigen-processing pathway. Immunol. Rev. 207, 31-41 (2005).
3. Yewdell, J.W. Plumbing the sources of endogenous MHC class I peptide ligands. Curr. Opin. Immunol. 19, 79-86 (2007).
4. Reits, E. et al. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 20, 495-506 (2004).
5. York, I.A. et al. The cytosolic endopeptidase, thimet oligopeptidase, destroys antigenic peptides and limits the extent of MHC class I antigen presentation. Immunity 18, 429-440 (2003).
6. Saric, T., Graef, C.I. & Goldberg, A.L. Pathway for degradation of peptides generated by proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. J. Biol. Chem. 279, 46723-46732 (2004).
7. Saveanu, L. et al. Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat. Immunol. 6, 689-697 (2005).
8. Craiu, A., Akopian, T., Goldberg, A. & Rock, K.L. Two distinct proteolytic processes in the generation of a major histocompatibility complex class I-presented peptide. Proc. Natl. Acad. Sci. USA 94, 10850-10855 (1997).
9. Stoltze, L. et al. Generation of the vesicular stomatitis virus nucleoprotein cytotoxic T lymphocyte epitope requires proteasome-dependent and -independent proteolytic activities. Eur. J. Immunol. 28, 4029-4036 (1998).
10. Mo, X.Y., Cascio, P., Lemerise, K., Goldberg, A.L. & Rock, K. Distinct proteolytic processes generate the C and N termini of MHC class I-binding peptides. J. Immunol. 163, 5851-5859 (1999).
11. Benham, A.M., Gromme, M. & Neefjes, J. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading. J. Immunol. 161, 83-89 (1998).
12. Luckey, C.J. et al. Proteasomes can either generate or destroy MHC class I epitopes: evidence for nonproteasomal epitope generation in the cytosol. J. Immunol. 161, 112-121 (1998).
13. Schwarz, K. et al. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164, 6147-6157 (2000).
14. Luckey, C.J. et al. Differences in the expression of human class I MHC alleles and their associated peptides in the presence of proteasome inhibitors. J. Immunol. 167, 1212-1221 (2001).
15. Marcilla, M., Cragnolini, J.J. & Lopez de Castro, J.A. Proteasome-independent HLA-B27 ligands arise mainly from small basic proteins. Mol. Cell. Proteomics 6, 923-938 (2007)
16. Seifert, U. et al. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat. Immunol. 4, 375-379 (2003).
17. Parmentier, N. et al. Production of an antigenic peptide by insulin-degrading enzyme. Nat. Immunol. 11, 449-454 (2010).
18. van Endert, P. Role of tripeptidyl peptidase II in MHC class I antigen processing -the end of controversies? Eur. J. Immunol. 38, 609-613 (2008).
19. Tenzer, S. et al. Modeling the MHC class I pathway by combining predictions of proteasomal cleavage, TAP transport and MHC class I binding. Cell. Mol. Life Sci. 62, 1025-1037 (2005).
20. Kessler, J.H. et al. Effcient identifcation of novel HLA-A(*)0201- presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis. J. Exp. Med. 193, 73-88 (2001).
21. Geier, E. et al. A giant protease with potential to substitute for some functions of the proteasome. Science 283, 978-981 (1999).
22. Fumagalli, P. et al. Human NRD convertase: a highly conserved metalloendopeptidase expressed at specifc sites during development and in adult tissues. Genomics 47, 238-245 (1998).
23. Chow, K.M. et al. Studies on the subsite specifcity of rat nardilysin (N-arginine dibasic convertase). J. Biol. Chem. 275, 19545-19551 (2000).
24. Chow, K.M. et al. Nardilysin cleaves peptides at monobasic sites. Biochemistry 42, 2239-2244 (2003).
25. Knight, C.G., Dando, P.M. & Barrett, A.J. Thimet oligopeptidase specifcity: evidence of preferential cleavage near the C-terminus and product inhibition from kinetic analysis of peptide hydrolysis. Biochem. J. 308, 145-150 (1995).
26. Oliveira, V. et al. Temperature and salts effects on the peptidase activities of the recombinant metallooligopeptidases neurolysin and thimet oligopeptidase. Eur. J. Biochem. 269, 4326-4334 (2002).
27. Oliveira, V. et al. Substrate specifcity characterization of recombinant metallo oligo-peptidases thimet oligopeptidase and neurolysin. Biochemistry 40, 4417-4425 (2001).
28. van Swieten, P.F. et al. A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome. Bioorg. Med. Chem. Lett. 17, 3402-3405 (2007).
29. + T cell response against HIV-1. PLoS Med. 3, e403 (2006).
30. Brooks, J.M., Murray, R.J., Thomas, W.A., Kurilla, M.G. & Rickinson, A.B. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J. Exp. Med. 178, 879-887 (1993).
31. Sigman, J.A. et al. Flexibility in substrate recognition by thimet oligopeptidase as revealed by denaturation studies. Biochem. J. 388, 255-261 (2005).
32. Kawakami, Y. et al. Identifcation of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infltrating lymphocytes. J. Exp. Med. 180, 347-352 (1994).
33. Romero, P. et al. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma. J. Immunol. 159, 2366-2374 (1997).
34. Le Gall, S., Stamegna, P. & Walker, B.D. Portable fanking sequences modulate CTL epitope processing. J. Clin. Invest. 117, 3563-3575 (2007).
35. Schneider, J., Brichard, V., Boon, T., Meyer zum Buschenfelde, K.H. & Wolfel, T. Overlapping peptides of melanocyte differentiation antigen Melan-A/MART- 1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int. J. Cancer 75, 451-458 (1998).
36. Silva, C.L., Portaro, F.C., Bonato, V.L., de Camargo, A.C. & Ferro, E.S. Thimet oligopeptidase (EC 3.4.24.15), a novel protein on the route of MHC class I antigen presentation. Biochem. Biophys. Res. Commun. 255, 591-595 (1999).
37. Portaro, F.C. et al. Thimet oligopeptidase and the stability of MHC class I epitopes in macrophage cytosol. Biochem. Biophys. Res. Commun. 255, 596-601 (1999).
38. Saric, T. et al. Major histocompatibility complex class I-presented antigenic peptides are degraded in cytosolic extracts primarily by thimet oligopeptidase. J. Biol. Chem. 276, 36474-36481 (2001).
39. Kim, S.I., Pabon, A., Swanson, T.A. & Glucksman, M.J. Regulation of cell-surface major histocompatibility complex class I expression by the endopeptidase EC3.4.24.15 (thimet oligopeptidase). Biochem. J. 375, 111-120 (2003).
40. Berti, D.A. et al. Analysis of intracellular substrates and products of thimet oligopeptidase (EC 3.4.24.15) in human embryonic kidney 293 cells. J. Biol. Chem. 284, 14105-14116 (2009).
41. Herberts, C.A. et al. Cutting edge: HLA-B27 acquires Many N-terminal dibasic peptides: coupling cytosolic peptide stability to antigen presentation. J. Immunol. 176, 2697-2701 (2006).
42. Csuhai, E., Chen, G. & Hersh, L.B. Regulation of N-arginine dibasic convertase activity by amines: putative role of a novel acidic domain as an amine binding site. Biochemistry 37, 3787-3794 (1998).
43. Mulder, A. et al. Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol. Immunol. 47, 809-815 (2010).
44. Kessler, J.H. et al. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fuorescein-labeled synthetic peptides. Hum. Immunol. 64, 245-255 (2003).
45. Kessler, B.M. et al. Extended peptide-based inhibitors effciently target the proteasome and reveal overlapping specifcities of the catalytic beta-subunits. Chem. Biol. 8, 913-929 (2001).
46. Balow, R.M., Tomkinson, B., Ragnarsson, U. & Zetterqvist, O. Purifcation, substrate specifcity, and classifcation of tripeptidyl peptidase II. J. Biol. Chem. 261, 2409-2417 (1986).
47. Tomkinson, B. & Zetterqvist, O. Immunological cross-reactivity between human tripeptidyl peptidase II and fbronectin. Biochem. J. 267, 149-154 (1990).
48. Roelse, J., Gromme, M., Momburg, F., Hammerling, G. & Neefjes, J. Trimming of TAP-translocated peptides in the endoplasmic reticulum and in the cytosol during recycling. J. Exp. Med. 180, 1591-1597 (1994).
49. Neisig, A. et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I- presentable peptides and the effect of fanking sequences. J. Immunol. 154, 1273-1279 (1995).
50. Androlewicz, M.J. & Cresswell, P. Human transporters associated with antigen processing possess a promiscuous peptide-binding site. Immunity 1, 7-14 (1994).